

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 80673

**Title:** Gefitinib improves severe bronchorrhea and prolongs the survival of a patient with lung invasive mucinous adenocarcinoma: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05352593

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Reviewer Country

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-10-09

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-11-21 21:00

**Reviewer performed review:** 2022-11-23 20:14

**Review time:** 1 Day and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

#### **SPECIFIC COMMENTS TO AUTHORS**

Thank you for inviting me to read this manuscript. This article reports a case of a patient with lung-invasive mucinous adenocarcinoma and a positive epidermal growth factor receptor (EGFR) mutation treated with gefitinib (EGFR-tyrosine kinase inhibitor). The patient had an adequate response to treatment. The article is well-written and easy to read. I have two comments: Introduction: • The authors must describe the mechanics of the action of gefitinib in the introduction. Discussion: • The authors must highlight that this is the first report that describes an adequate response with gefitinib in this clinical setting.